News
8.9.22

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

TOPADUR Pharma AG has been selected among Switzerland's most promising scale-ups in 2022. Huge thanks to everyone of our team, supporters, and partners believing in us along the way!

Please check out the link below.

‍

Download DocumentDokument herunterladenhttps://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022
8.10.20
News

Interview with Reto Naef, CEO of TOPADUR PHARMA AG

The Switzerland Global Enterprise interviewed Reto Naef, CEO of TOPADUR PHARMA AG.

Read more
20.5.20
News

Scientific Publication in the Journal of Investigative Dermatology

A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Promotes Wound Healing in Normal and Diabetic Mice.

Read more
7.9.23
News

TOPADUR has been selected as a TOP 100 Scale-up 2023 with unicorn potential

We are proud to be recognized as one of Switzerland's most promising scale-ups in 2023.

Read more

About us

NewsHistoryResearch PartnersCareers

Approach

Topadur CompoundsKey publications

Disease Areas

Lung FibrosisOncologyMedical cosmeticsOphthalmologySkin FibrosisWound Healing

Investors

Investors
info@topadur.com+41 44 755 44 66
Topadur Pharma AG | Grabenstrasse 11A, 8952 Schlieren, Switzerland
ImpressumLegal Disclaimer